@article{a1f89af712ee4ad28d0cb027cff1cb7e,
title = "Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis",
author = "Joselle Cook and Gonsalves, \{Wilson I.\} and Gertz, \{Morie A.\} and Alissa Visram and Rahma Warsame and Lacy, \{Martha Q.\} and Angela Dispenzieri and David Dingli and Prashant Kapoor and Kourelis, \{Taxiarchis V.\} and Hayman, \{Suzanne R.\} and Kyle, \{Robert A.\} and Eli Muchtar and Kumar, \{Shaji K.\} and Hogan, \{William J.\} and Jacob, \{Eapen K.\} and Buadi, \{Francis K.\}",
note = "Funding Information: AD: Alnylam: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Takeda: Research Funding; Intellia: Research Funding; Pfizer: Research Funding. DD: Grant/Research funding from Juno, Celgene. MG: personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, and Celgene personal fees from Research to Practice, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Development of educational materials for i3Health. Educational Program development i3Health. Royalties from Springer Publishing. Grant Funding Amyloidosis Foundation; International Waldenstrom Foundation. NCI SPORE MM SPORE 5P50 CA186781-04 PK: Research funding (Takeda, Celgene, and Amgen). SK: Consulting or advisory Role with Takeda, Janssen Oncology, Amgen, AbbVie, Merck, Celgene, Genentech/Roche, Oncopeptides, Kite, a Gilead company, Genecentrix, Molecular Partners, Bluebird Bio, Cellectar and research Funding: Celgene, Takeda, AbbVie, Novartis, Sanofi, Janssen Oncology, Merck, Kite, a Gilead company, MedImmune, Roche/Genentech, TeneoBio, CARsgen Therapeutics. MQL: Research funding (Celgene) ",
year = "2022",
month = jun,
doi = "10.1038/s41409-022-01659-w",
language = "English (US)",
volume = "57",
pages = "1007--1009",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Springer Nature",
number = "6",
}